|
|
 | | | |
- close
- close
- close
- close
FiercePharma
Oct 15
Comment
Poor Lamberto Andreotti. Just a year ago, the Bristol-Myers Squibb ($BMY) CEO was accepting bouquets for his company's better-than-the-rest reputation in Big Pharma. Now, he's nominated as the year's worst CEO.
What happened? Inhibitex, for one...
FierceBiotech
Oct 15
Comment
Bristol-Myers Squibb's ($BMY) "string of pearls" is starting to look a little dull to investors. After watching its expensive hepatitis C drug from Inhibitex go up in flames while regulators slowed the progress of its blood-thinner Eliquis, its...
FierceBiotech
Aug 23
Comment
Less than 8 months after Bristol-Myers Squibb ($BMY) bought out Inhibitex and its lead hepatitis C drug for $2.5 billion, the company has officially opted to write off the therapy as a complete waste of money and a potential threat to human...
FierceBiotech
Aug 6
Comment
Bristol-Myers Squibb ($BMY) is weighing whether to write down the value of its experimental hepatitis C pill BMS-986094, which has a carrying cost of $1.8 billion, according to the company's SEC filing on Friday. The statement came days after the...
FiercePharma
Aug 2
Comment
In January, Bristol-Myers Squibb ($BMY) paid $2.5 billion for Inhibitex, jazzed by the prospects for its hepatitis C drug candidate. Now, 7 months later, that drug is in deep trouble. The company stopped dosing in a Phase IIb trial after one...
MarketWatch
Aug 2
Comment
Shares of pharmaceutical maker Bristol-Myers Squibb fell 7% to $33.05 in early trading Thursday after it said it was halting a key clinical trial for its hepatitis C drug candidate INX-189 over safety concerns. Bristol-Myers said it has suspended...
StreetInsider.com
Feb 13
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Bristol-Myers+Squibb+%28BMY%29+Completes+Inhibitex+%28INHX%29+Acquisition/7169096.html for the full story.
Marketwire
Feb 7
Comment
HONG KONG -- (Marketwire) -- 02/07/12 -- Today, www.BollingerReport.com introduced featured coverage of Inhibitex, Inc. (NASDAQ: INHX) and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX). Full research reports are available to readers at:
Benzinga
Feb 3
Comment
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
StreetInsider.com
Feb 3
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Bristol-Myers+Squibb+%28BMY%29+Moves+One+Step+Closer+to+Completing+Inhibitex+%28INHX%29+Acquisition/7134305.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
